Clemastin

Quick links to important sections

Clemastin

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clemastin

Quick Facts

Property Description
Active ingredient Clemastine fumarate
Pharmacological class First-generation antihistamine
Forms Tablet, Solution for injection (ampoules), Syrup
Origin Synthetic compound (Ethanolamine derivative)
Common purpose General relief from allergic reactions

What Type of Medicine is Clemastine?

Clemastine is a synthetic compound precisely classified as a potent antihistamine and a selective histamine H₁-receptor antagonist. This medication works by blocking the effects of the body's natural allergic messenger, histamine. It is generally prepared using the salt form, Clemastine fumarate, which is the standardized active ingredient and a single-ingredient product designed for pharmacological consistency. Its specific chemical profile, supported by pharmacological studies, ensures a rapid onset of action, a feature clinically recognized for its benefit in acute allergic episodes.


What are the Available Forms and General Purpose of Clemastine?

The medication is produced in several pharmaceutical preparations to suit different clinical requirements, including the tablet and syrup for oral intake, as well as a sterile solution for injection in ampoules for parenteral use. The syrup formulation, specifically, addresses the needs of pediatric patients who may require a liquid form. The general purpose of Clemastine is to provide rapid relief from the uncomfortable symptoms associated with allergic reactions, such as generalized itching or a sudden rash. This confirms the drug is a reliable option for quickly reducing symptoms caused by hypersensitivity.


Clemastine’s Mechanism: Why is it a First-Generation Antihistamine?

Clemastine is classified as a first-generation antihistamine because of its molecular characteristics, which allow it to easily perform antagonism of H₁-receptors. This action directly prevents histamine from binding to its target sites. This classification is a key differentiating factor from non-sedating second-generation agents. The mechanism is a well-established pharmacological principle, confirming its utility in quickly mitigating acute allergic responses across various body systems.

Regulatory References

  1. FDA Drug Label

What side effects are possible with Clemastin?

Possible Side Effects and Safety Information

The official safety profile for Clemastine fumarate primarily focuses on effects associated with its classification as a first-generation antihistamine, affecting multiple physiological systems. Adverse reactions are systematically documented by system-organ class, including the Nervous System, Gastrointestinal System, and Cardiovascular System.

The most frequent adverse reactions listed in regulatory labeling are often related to CNS depression and anticholinergic activity. These effects include sedation, sleepiness, dizziness, fatigue, and dryness of the mouth, nose, and throat. Other documented effects involve disturbed coordination, nausea, vomiting, and changes in blood pressure, such as hypotension.

Serious adverse reactions, though rare, are officially documented and include the potential for anaphylactic shock and severe hematologic effects like agranulocytosis and hemolytic anemia. The label also notes that initial overdosage reactions in children may involve CNS stimulation.

Safety constraints are defined for specific groups. Antihistamines are more likely to cause dizziness, sedation, and hypotension in older adults. Clemastine is officially contraindicated in nursing mothers. Caution is required when the medicine is used in individuals with pre-existing conditions such as narrow angle glaucoma, hypertension, or certain cardiovascular diseases, as defined in the official prescribing information. Additionally, the label notes that using Clemastine with other CNS depressants, including alcohol, may result in additive CNS depression.

Overdose and Emergency Response

The official regulatory profile for Clemastine overdosage details potential manifestations that range from Central Nervous System (CNS) depression to CNS stimulation. The label documents severe outcomes including convulsions and the risk of subsequent cardio respiratory arrest. Overdose requires immediate response and professional medical evaluation.


Documented Overdose Manifestations and Emergency Action

Aspect Official Regulatory Statement
CNS Effects Overdosage may present with symptoms ranging from CNS depression to CNS stimulation, alongside atropine-like signs such as fixed, dilated pupils and flushing.
Severe Outcomes Life-threatening outcomes include convulsions and the risk of cardio respiratory arrest.
Pediatric Notes CNS stimulation predominates initially in children, which may include excitement, hyperthermia, and tremors.
Action Mandated Seek emergency medical attention or contact a Poison Control Center right away.

Supportive Management Procedures

Management procedures outlined in regulatory information focus on supportive measures. These may include gastric lavage using isotonic or 1/2 isotonic saline and the use of saline cathartics for gastrointestinal evacuation. CNS stimulants should not be used in the management of overdose. Precautions against aspiration must be taken, particularly in infants and children, due to the specific risks documented in this population.

Therapeutic Uses of Clemastin

Clemastine is commonly used for managing symptoms associated with acute or episodic allergic manifestations, generally offering supportive therapeutic benefit during periods of heightened distress. The medication is relevant in clinical settings that involve acute or disruptive symptom patterns, and where additional symptomatic support is needed.


Key Therapeutic Applications and Benefits

Clemastine is considered relevant in conditions characterized by periods of heightened symptoms, including allergic rhinitis (hay fever), allergic conjunctivitis, and certain uncomplicated allergic skin reactions like hives (urticaria) and angioedema. It is commonly used when groups of symptoms appear suddenly and interfere with daily comfort. It may assist with symptomatic relief for manifestations such as constant sneezing, generalized itching (pruritus), profuse runny nose, and bothersome watery eyes. This supports general well-being during symptomatic phases and assists with maintaining functional stability.


Quick Fact: Symptom Focus
Primary Use Supports relief from allergic symptoms that interfere with daily comfort
Symptom Cluster Addresses rhino-ocular discomfort and dermal manifestations
Context of Use Applied during phases of acute or episodic symptomatic burden

Regulatory References

  1. DailyMed (U.S. National Library of Medicine)

Eligibility and Restrictions for Use

Who Can and Cannot Use Clemastine? — Official Regulatory Information

Regulatory documents strictly define the eligible and restricted populations for Clemastine use.

Contraindications and Exclusions

Status Population/Condition
Contraindicated Nursing Mothers (due to risk of adverse reactions in infants)
Contraindicated Newborn or Premature Infants
Contraindicated Patients with Hypersensitivity to clemastine or other similar antihistamines
Contraindicated Treatment of Lower Respiratory Tract Symptoms, including asthma
Contraindicated Patients currently receiving Monoamine Oxidase (MAO) Inhibitor therapy

Age-Related Eligibility

  • Children under 2 years of age (OTC): Use is not recommended.
  • Children under 6 years of age (Syrup/Solution): Safety and efficacy have not been established.
  • Children under 12 years of age (Tablets): Safety and efficacy have not been established.
  • Elderly Patients (approx 60 years or older): Use requires considerable caution due to increased susceptibility to dizziness, sedation, and hypotension.

Conditional Use (Caution Advised)

Clemastine should be used with considerable caution in patients with pre-existing conditions that may be aggravated by its properties, including:

  • Narrow-angle glaucoma or increased intraocular pressure.
  • Stenosing peptic ulcer or pyloroduodenal obstruction.
  • Symptomatic prostatic hypertrophy or bladder neck obstruction.
  • History of bronchial asthma, hyperthyroidism, cardiovascular disease, and hypertension.

Pregnancy Status

Use during pregnancy should occur only if clearly needed, as experience with the drug in pregnant women is inadequate to definitively determine the potential for harm.

What should I know about interactions with other medicines?

Clemastine Interactions with other medicines and products

The following interaction information is based strictly on documentation provided by governmental regulatory bodies, such as the U.S. Food and Drug Administration (FDA) prescribing information and international product summaries.


Formal Contraindications and Pharmacodynamic Effects

The primary focus of Clemastine's official interaction profile is the risk of pharmacodynamic enhancement, meaning the effects of co-administered substances may be intensified.

Interaction Type Interacting Substances/Classes
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs)
Additive CNS Depression CNS Depressants (e.g., Sedatives, Hypnotics, Tranquilizers)
Additive Effects Alcohol (Ethyl Alcohol)

Regulatory Details and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated because these agents are documented to prolong and intensify the anticholinergic effects of Clemastine.

Clemastine should not be used concurrently with other Central Nervous System (CNS) depressants, including alcohol, as this combination may result in an additive effect that enhances the depressant action. Furthermore, official labeling notes a population-specific consideration: patients aged 60 years or older are more susceptible to the adverse effects of antihistamines, such as dizziness and sedation, which increases the clinical relevance of these additive interactions.

Mechanism of Action

Clemastin is a first-generation compound that functions as a selective histamine H1 receptor antagonist. It acts as a competitive inhibitor, binding to the H1 receptor sites located on the surface of target cells, thereby preventing the engagement and signaling cascade initiated by endogenous histamine. This blockade inhibits the downstream effects of histamine binding, specifically the activation of phospholipase C and the subsequent increase in intracellular IP3 (inositol triphosphate) and DAG (diacylglycerol), which are secondary messengers.

Clemastin also exhibits anticholinergic properties, acting as a non-selective antagonist at muscarinic acetylcholine receptors (mAChR), primarily the M1 subtype. This interaction modulates parasympathetic signaling pathways.

At the system level, the dual antagonism of H1 receptors and muscarinic receptors results in the modulation of vascular permeability and dilatation, and a reduction in glandular secretions in tissues such as the respiratory tract. Clemastin is lipophilic, allowing it to cross the blood-brain barrier and interact with H1 and mAChR targets within the central nervous system, influencing neuronal activity and vigilance.

Dosage and Administration Information

Clemastine fumarate is administered through the oral route using available pharmaceutical preparations, which include tablets and an oral solution or syrup. The approach to its use is defined by specific clinical guidelines.


Standard Usage Patterns

Category General Instructions for Use
Adult Dosing (≥ 12 years) Doses typically range from 1.34 mg to 2.68 mg per single administration. The maximum total daily dosage is 8.04 mg, intended for use under clinical supervision.
Frequency and Timing The medication is generally taken twice daily (every 12 hours) or may be taken up to three times daily in divided doses. It can be taken without reference to food.

Population and Administration Requirements

Dosage must be individualized based on patient response, with specific instructions governing use in certain populations. For children aged 6 to less than 12 years, the daily amount must not exceed 4.02 mg. For older adults (≥ 60 years), caution and dose reduction are recommended if initial mild sensitivity is observed.

When using the liquid form, it is necessary to measure the dose using a calibrated medical device to ensure accurate intake, rather than using a household spoon.

Additionally, the 2.68 mg tablet is scored, indicating it can be divided if an intermediate dose is required. The drug's usage pattern is primarily symptomatic, with dosing repeated as needed, up to the defined daily maximum.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clemastine

This overview describes the research landscape for Clemastine, focusing on the types of studies conducted and what the findings describe patterns observed in the studies so far. This information highlights what is known—and what is still uncertain—based on available scientific evidence.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial Allergies)

Research has primarily been conducted on Clemastine in studies exploring short-term symptom changes associated with allergic rhinitis, conditions characterized by fluctuating or episodic manifestations. These studies mostly involved short-term Randomized Controlled Trials (RCTs), which compared Clemastine against a placebo (an inactive substance) or against other antihistamines. The research focused on measuring outcomes related to physical discomfort, such as patient-reported scores for sneezing, runny nose, nasal congestion, and itching. Studies report how symptoms evolved in the observed populations over short follow-up durations. Evidence contributes to understanding symptom patterns in these controlled research settings. Long-term effects are not well characterized by extensive high-quality research.


Evidence for Use in Urticaria (Hives) and Itching

Clemastine was studied for its application in conditions involving periods of heightened symptoms, specifically urticaria (hives) and generalized itching. The evidence for this use is derived from settings with varying symptom burdens, including controlled trials and smaller, descriptive studies. In these studies, researchers monitored patient-reported outcomes describing perceived discomfort, such as scores for the severity and spread of hives. Research highlights changes measured during the study period for these outcomes, often over very short intervals. Evidence is limited by the fact that many studies relied on small sample sizes were modest, and long-term effects are not well characterized.


Key Evidence Gaps and Areas for Future Research

The existing evidence base, while contributing to understanding symptom patterns, still has several areas of uncertainty. Follow-up durations were limited in many controlled trials, which is a factor in understanding the effects of long-term use. Comparative evidence is lacking regarding Clemastine and newer antihistamines. Finally, the evidence quality varies across studies, and research focusing on its use in specific, vulnerable populations remains a key gap for future investigation. Evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Clemastine fumarate for symptomatic relief of allergic rhinitis (Symptom Relief RCT)
  2. Evidence Gaps in Clinical Trials of Pharmacologic Treatment for H1-Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review (Evidence Gaps/Population Data)

Frequently Asked Questions (FAQ)

Common questions about Clemastin (FAQ)


Q: Does Clemastin treat only seasonal allergies or year-round symptoms?

A: Official product information indicates that Clemastine is used for the symptomatic relief of allergic rhinitis. This diagnosis covers symptoms that may occur seasonally (e.g., hay fever) or year-round (perennial symptoms).


Q: What is the high-level difference between Clemastin and other over-the-counter allergy medicines?

A: Clemastine is classified as a first-generation antihistamine. A key difference from newer, second-generation medications is its ability to cross the blood-brain barrier more easily. This can result in a higher potential for side effects such as drowsiness and dry mouth, which are less common with newer agents.


Q: How long do the drowsy side effects of Clemastin usually last?

A: Regulatory documents on the drug's activity indicate that the antihistaminic effect generally lasts between 10 to 12 hours. However, in some individuals, effects like sedation may persist for up to 24 hours after taking a single oral dose.


Q: Are there specific reports of vision changes or blurred vision associated with Clemastin use?

A: Official patient information lists blurred vision as a potential effect associated with Clemastin use. The product labeling notes that caution is required for individuals with pre-existing eye conditions such as glaucoma.


Q: Can Clemastin be used by older adults (e.g., over 65) and are there special considerations?

A: Regulatory documents state that caution is required for patients 60 years of age and older. This is because older adults may be more susceptible to adverse effects, including dizziness, confusion, sedation, and low blood pressure, which increases the clinical relevance of interactions.


Q: What is the general guidance for people with asthma or other chronic breathing disorders regarding Clemastin?

A: According to official product labeling, Clemastine is contraindicated (should not be used) to treat lower respiratory tract symptoms, which includes acute asthma. Official labeling also lists a history of bronchial asthma as a condition that requires caution.


Q: Does Clemastin cure the cause of allergy symptoms or only provide symptomatic relief?

A: Official documentation indicates that Clemastine is used for the temporary relief of symptoms related to allergies and the common cold. Like most antihistamines, it works to mitigate the symptoms but does not cure the underlying cause of the allergic reaction.


Q: Is Clemastin also used to relieve symptoms associated with the common cold?

A: Yes, the official prescribing information notes that Clemastine is indicated for the temporary relief of symptoms associated with the common cold. These symptoms typically include a runny nose and sneezing.


Q: How quickly is Clemastin generally expected to start working?

A: Official pharmacological data indicates the medication is rapidly absorbed after taking a dose. Maximum antihistamine effect is typically reported to occur within 5 to 7 hours of administration.


Q: What is the typical duration of effect for a single dose of Clemastin?

A: Official product information describes the duration of effect for a single dose. The antihistamine effect usually lasts between 10 to 12 hours but may be sustained for as long as 24 hours in some individuals.


Q: Is there a typical time frame after which allergy symptoms should improve when taking Clemastin?

A: Regulatory documents indicate the maximal measured effect on allergic symptoms is reported within 5 to 7 hours after the medication is taken.


Q: Is confusion or mental fog an expected side effect of Clemastin?

A: Official safety profiles list confusion and nervousness as potential side effects. This is noted to occur with greater frequency in specific populations, such as older adults and children.


Q: Can Clemastin cause constipation or other stomach upset?

A: Yes, official safety information documents several gastrointestinal effects. Side effects that have been reported include constipation, nausea, and vomiting.


Q: Is excitement or nervousness a recognized side effect, particularly in children?

A: Regulatory documents note that in children, a paradoxical reaction can occur, sometimes involving excitement or nervousness. Central nervous system (CNS) stimulation has also been reported in cases of accidental overdosage in pediatric patients.


Q: Can Clemastin be linked to an inability to empty the bladder (urinary retention)?

A: The official label warns that the drug may cause difficulty in emptying the bladder, which is known as urinary retention. The labeling notes that caution is required for individuals with related conditions like an enlarged prostate.


Q: Are fast or irregular heartbeats a potential, though rare, side effect of Clemastin?

A: Although rare, official safety information documents severe cardiovascular effects. These include the potential for fast, pounding, or irregular heartbeat (palpitations or tachycardia).


Q: Is a headache a commonly reported side effect when taking Clemastin?

A: Official patient information lists a headache as one of the potential side effects associated with this medication.


Q: Are there any reports of Clemastin affecting mucus thickness in the lungs?

A: Official regulatory documents indicate that the drug's properties can cause mucus in the lungs to dry up and thicken. This is why the official labeling notes that caution is required for people with certain respiratory conditions.


Q: Is Clemastin associated with an increased risk of sun sensitivity?

A: Official patient information notes that Clemastine may cause photosensitivity, which is an increased sensitivity to sunlight. Official patient information notes that protective measures against sun exposure are often advised.


Q: What kinds of other medications may interact with Clemastin?

A: Regulatory documents highlight several classes of medications that may interact with Clemastine. These include CNS depressants (such as sedatives or tranquilizers) and Monoamine Oxidase Inhibitors (MAOIs).


Q: Are there specific categories of drugs that should not be taken near the time of taking Clemastin?

A: Official safety labeling specifies two categories of substances that should not be taken at the same time: Monoamine Oxidase Inhibitors (MAOIs) and any other agent that acts as a Central Nervous System (CNS) depressant, which includes alcohol.


Q: Can Clemastin interact with herbal supplements or over-the-counter cold medicines?

A: Official patient instructions state that the use of all herbal products and over-the-counter (OTC) medicines should be discussed with a healthcare provider. This is because many OTC cold or sleep aids can also be CNS depressants, increasing the risk of additive effects.


Q: Is there a risk of interaction with certain drugs used for mood or mental health conditions?

A: The product is formally contraindicated (should not be used) with MAO inhibitors, a drug class sometimes used for depression. Other mood or mental health medications that act as CNS depressants also carry a risk of combined side effects.


Q: Can Clemastin affect the results of standard allergy skin tests?

A: Official patient advice states that the medication can affect the results of standard allergy skin tests. Therefore, official patient information notes that individuals taking Clemastine need to inform the healthcare provider performing the test.


Q: Are there known interactions between Clemastin and common non-prescription pain relievers?

A: While common non-prescription pain relievers do not typically have a direct interaction, caution is advised if the pain reliever is a combination product. These products may contain other ingredients classified as CNS depressants, which could lead to an additive effect with Clemastin.


Q: Do foods or specific diets affect how Clemastin works?

A: Official product information indicates that the drug can be taken with or without food. There are no specific restrictions on foods or drinks, though taking it with a meal might help reduce the chance of stomach upset.


Q: Is it necessary to inform a healthcare provider or dentist about Clemastin use before surgery?

A: Official patient instructions state that all healthcare providers, including dentists and any professionals performing surgery, should be informed that the patient is currently taking Clemastine.


Q: What are the general regulatory recommendations for using Clemastin during pregnancy?

A: Regulatory documents state that use during pregnancy should occur only if clearly needed. This is because experience with the drug in pregnant women is considered inadequate to definitively determine the potential for harm to the fetus.


Q: What underlying health conditions might generally make a person ineligible to use Clemastin?

A: Official regulatory documents list conditions that make a person generally ineligible. These include being a nursing mother, having a known hypersensitivity to the drug, or currently receiving a Monoamine Oxidase Inhibitor (MAOI).

How should Clemastin be stored and disposed of?

Clemastine must be stored strictly according to the conditions defined by the official labeling to maintain its stability. The medication should be kept at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F).

It must be stored in its original, tightly closed container and protected from excess heat, direct sunlight, and moisture. A mandatory requirement across all regulatory jurisdictions is that the medicine must be stored out of the reach and sight of children.

For disposal, unused or expired Clemastine should not be flushed down a toilet or poured into a drain. The officially recommended method is to return the product to an authorized drug take-back program. If no program is available, it can be safely discarded with household trash after being mixed with an unappealing substance, adhering to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clemastin found in:

A-Z Index: